AF
SMMT icon

Amalgamated Financial’s Summit Therapeutics SMMT Stock Holding History

Amalgamated Financial’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$11K Buy
+4,291
New +$10.8K ﹤0.01% 2881

Other funds holding SMMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Amalgamated Financial's SMMT Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Summit Therapeutics (SMMT) in Q1 2022: 4,291 shares worth $11K. The stake represents ﹤0.01% of the portfolio and ranks #2881 among its holdings.

52 funds tracked by Wall St. Rank hold SMMT as of Q1 2022.

  • Amalgamated Financial held 4,291 shares of Summit Therapeutics worth $11K as of Q1 2022.
  • Summit Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Summit Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2881 holding.
  • 52 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.